Recently Updated Advisory Committee Materials
-
-
-
-
Posted on July 24, 2012
Cardiovascular and Renal Drugs Advisory Committee
- Transcript for the May 23, 2012 Meeting of the Cardiovascular and Renal Drugs Advisory Committee (PDF - 706KB)
- 2012 Meeting Materials, Cardiovascular and Renal Drugs Advisory Committee
-
-
-
-
Posted on July 23, 2012
Dermatologic and Ophthalmic Drugs Advisory Committee
- Briefing Information for the July 26, 2012 Meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee
- ThromboGenics Briefing Information, Jetrea (Ocriplasmin Intravitreal Injection), for the July 26, 2012 Meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee (PDF – 6.96MB) (PDF - 6.8MB)
- FDA Briefing Information, Jetrea (Ocriplasmin Intravitreal Injection), for the July 26, 2012 Meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee (PDF – 986KB) (PDF - 986KB)
- Genentech Briefing Information, Lucentis (Ranibizumab Injection), for the July 26, 2012 Meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee (PDF – 7.02MB) (PDF - 6.9MB)
- FDA Briefing Information, Lucentis (Ranibizumab Injection), for the July 26, 2012 Meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee (PDF – 1.05MB) (PDF - 1MB)
- Webcast Information for the July 26, 2012 Meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee (PDF - 13KB)
- Committee Roster for the July 26, 2012 Meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee (PDF - 28KB)
- Draft Meeting Roster for the July 26, 2012 Meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee (PDF - 56KB)
- Draft Questions for the July 26, 2012 Meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee (PM Session) (PDF - 20KB)
- Draft Questions for the July 26, 2012 Meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee (AM Session) (PDF - 39KB)
- Draft Agenda for the July 26, 2012 Meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee (PDF - 49KB)
- 2012 Meeting Materials, Dermatologic and Ophthalmic Drugs Advisory Committee
-
Psychopharmacologic Drugs Advisory Committee
-
No hay comentarios:
Publicar un comentario